ArticleJournal of cardiothoracic surgery2025
GPER1-mediated suppression of acute cellular rejection in murine cervical heart transplantation by estradiol.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to investigate the inhibitory effect of estradiol (E2) on acute cellular rejection following murine cervical heart transplantation and the role of G protein-coupled estrogen receptor 1 (GPER1).
methodA murine cervical heart transplantation model was established and categorized into four groups: syngeneic group (C57BL/6 to C57BL/6), allogenic control group (BALB/c to C57BL/6), E2 group (BALB/c to C57BL/6), and E2 + G15 group (G15: one of GPER1 blocker) (BALB/c to C57BL/6). Survival time, pathological rejection grade, intimal hyperplasia area of coronary artery in donor heart, mRNA expression levels of TGF-β, IL-10, and Foxp3 in spleen, and protein expression levels of CD4 and CD25 in spleen membrane proteins, were compared among these groups.
resultsThe syngeneic group showed 100% survival, while survival in the allogenic control group was significantly reduced. E2 treatment prolonged survival compared to the allogenic control group, but survival decreased with the addition of E2 + G15. Rejection was reduced in the E2 group compared to the allogenic control group, whereas the E2 + G15 group exhibited increased rejection compared to the E2 group. Intimal hyperplasia was absent in the syngeneic group, significant in the allogenic control group, reduced in the E2 group compared to the allogenic control group, but greater in the E2 + G15 group compared to the E2 group. The expression of IL-10, Foxp3, and TGF-β in the allogenic control group was higher than in the syngeneic group. In the E2 group, IL-10, Foxp3, and CD25 were higher than in the allogenic control group, while TGF-β and CD4 expression were lower. The E2 + G15 group had lower IL-10, Foxp3, and CD25 expression but higher TGF-β expression than the E2 group.
conclusionSevere acute cellular rejection was observed following murine cervical heart transplantation. E2 suppresses acute rejection by enhancing Treg cell expression, mediated by GPER1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.